NIDA supports epidemiology, policy investigate and general public wellbeing outcomes investigate linked to cannabis use, such as the Monitoring the long run study and a medicinal cannabis use registry.In 2024, the U.S. Drug Enforcement Administration (DEA) indicated which they plan to reclassify marijuana to be a Program III drug. This rescheduling